Measured Wealth Private Client Group LLC Makes New Investment in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Key Points

• Measured Wealth Private Client Group LLC acquired a new stake in Jazz Pharmaceuticals, purchasing 3,301 shares valued at approximately $410,000.
• Jazz Pharmaceuticals reported a quarterly loss of ($8.25) earnings per share, missing the consensus estimate and showing a negative net margin of 9.91%.
• Institutional investors own 89.14% of Jazz Pharmaceuticals' stock, indicating strong confidence in the company among larger investment entities.

Measured Wealth Private Client Group LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,301 shares of the specialty pharmaceutical company's stock, valued at approximately $410,000.

A number of other large investors have also made changes to their positions in JAZZ. Quadrant Capital Group LLC increased its stake in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares during the period. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals in the first quarter valued at about $25,000. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares during the period. Parallel Advisors LLC increased its stake in Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 119 shares during the period. Finally, Picton Mahoney Asset Management grew its stake in Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 269 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several research analyst reports. Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective on the stock. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $181.43.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded up $2.58 during mid-day trading on Tuesday, hitting $113.33. 772,582 shares of the company traded hands, compared to its average volume of 967,463. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The business has a 50-day moving average of $111.32 and a 200 day moving average of $117.39. The stock has a market capitalization of $6.87 billion, a price-to-earnings ratio of -16.84, a PEG ratio of 5.15 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the prior year, the company earned $5.30 earnings per share. The company's quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.